Mind Medicine (MindMed) Inc. Completes $13.2 Million Bought Deal Prospectus Offering

May 26, 2020

Mind Medicine (MindMed) Inc., a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering, completed a bought deal prospectus offering of 24,953,850 units for aggregate gross proceeds of $13,225,541. The offering was led by Eight Capital as sole bookrunner and underwriter.

Wildeboer Dellelce LLP acted for MindMed in connection with the offering with a team comprised of Perry Dellelce, Peter Volk, Rebecca Cochrane, Jeff Bookman and Natalie Tershakowec (corporate/securities) and Katy Pitch and Marija Tasevska (tax).